- Last Thursday, a panel of FDA advisers met and endorsed Paxlovid, a step towards full approval of the COVID-19 treatment that currently has emergency use authorization. The panel found that Paxlovid significantly decreased hospitalizations and death. While some people who took Paxlovid experienced “rebounds,” in which symptoms returned, the panel found that some people who did not take Paxlovid also experienced COVID rebounds. If you test positive for COVID-19, talk to your healthcare provider about Paxlovid or find a test-to-treat location near you.
- The Kaiser Family Foundation recently reviewed 3 years of COVID-19 data, including data related to racial disparities. Currently, people who identify as Black or Hispanic are about half as likely as their white counterparts to have received an updated bivalent booster. These racial disparities point to the continued importance of our work to build vaccine confidence, even as the third year of the pandemic comes to a close.
Download video in English and Spanish.
Download audio in English and Spanish. |